

QR Pharma receives FDA clearance to conduct clinical trials with its second novel Alzheimer compound, Bisnorcymserine

Radnor, PA, December 2, 2010: [QR Pharma, Inc.](#), a developer of novel drugs to treat Alzheimer's disease (AD), announced today that the United States Food and Drug Administration (FDA) *has accepted the* Investigational New Drug application (IND) to begin human clinical trials and evaluate the safety and efficacy of the company's second product, [bisnorcymserine](#) (BNC). "Receiving clearance to move into clinical studies for BNC is a significant milestone for QR Pharma," said Maria Maccicchini, CEO of QR Pharma.

BNC was discovered by [Dr. Nigel Greig](#) in his laboratory at the National Institutes of Health/National Institute on Aging (NIH/NIA). The compound targets AD via selective butyrylcholinesterase inhibition (BChEI) as well as with a disease modifying activity via amyloid precursor protein (APP) inhibition. All preclinical *in vitro* and *in vivo* work for BNC - toxicology, pharmacokinetics (PK) and pharmacodynamics (PD) - has been completed. BNC was found to be safe and have excellent half-life. It has an interesting preclinical profile making it suitable for clinical development in patients suffering from AD and dementia.

Since BChE is elevated in advanced AD patients, studies suggest that the compound may improve cognition in later stage AD patients. BNC complements the lead compound, [Posiphen®](#), which is intended to treat mild cognitive impaired and early AD patients. BNC provides a unique opportunity to improve on existing cholinesterase inhibition and marry improvements in cognition to slowing of the disease to obtain a better outcome for AD.

About QR Pharma, Inc. Headquartered in Radnor, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment, Alzheimer's disease (AD), Parkinson's disease (PD) and Down Syndrome (DS). QR has two product development programs based on oral small molecules that readily pass the blood-brain barrier and target two distinct pathways for the treatment of AD. QR Pharma has raised over \$3 million from [BenFranklin](#), [BioAdvance](#), angels and Federal grants. www.qrpharma.com

Contact: Claudia Muntean, MBA
Tel: 610-209-8454
Fax: 484 253 2288
muntean@qrpharma.com
www.qrpharma.com